2[8]Wen M, Segerer S, Dantas M,et al. Renal injury in Apolipoprotein E-Deficient mice. Lab Invest, 2002 ,82:999 被引量：1
3[12]Li LS, Liu ZH, Ji DX,et al. Novel effective treatment of lipoprotein glomerulopathy-immunoadsorption onto protein A. J Am Soc Nephrol, 2001,12:A0592 被引量：1
4[13]Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis, 2003,41:244 被引量：1
5[14]Arai T, Yamashita S, Yamane M,et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis, 2003,169: 293 被引量：1
6[15]Nakaji S. Current Topics on immunoadsorption therapy. Therapeutic apheresis,2001,5:301 被引量：1
7[16]Andrews PA, O'Donnell PJ, Dilly SA,et al. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant,1997,12:2442 被引量：1
8[4]Richard P, Thomas G, Pascual de Zulueta M, et al. Common and rare genotype of human apoprotein E determined by specific restriction profiles of polymerase chain reaction amplified DNA. Clin Chem, 1994, 40:24 被引量：1
9[5]Saito T,Sato H,Oikawa S. Lipoprotein glomerulopathy : A new aspect of lipid induced glomerular injury. Nephrology,1995,1:17 被引量：1
10[6]Gerdes LU. The common polymorphism of apolipoprotein E: geographical aspects and new pathophysiological relations. Clin Chem Lab Med, 2003, 41: 628 被引量：1
10Salaguchi H, Mitaral Y, Hirose S, et al. Lipoprotein glomerulopathy-a new disease with specific histological findings[J]. Jpn JNephnol, 1987(31):451. 被引量：1
